At 95, Warren Buffett proves he’s still the sharpest dealmaker with $10 billion OxyChem deal ⊕
The transaction reflects Buffett's investment acumen: buying a good business at an attractive price, while skirting the possibility of costly headaches.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.